Purinf
Post-Infectious Disorder
Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
All Natural Medicine Clinic, LLC
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04846010CT.gov Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Post-Infectious Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Purinf (this asset) | All Natural Medicine Clinic, LLC | P1/2 | CCC · 48 |
| Furfat | All Natural Medicine Clinic, LLC | P1/2 | CCC |
| Purclo | All Natural Medicine Clinic, LLC | P1/2 | CCC |
| Purphl | All Natural Medicine Clinic, LLC | P1/2 | CCC |
| Smoliv | All Natural Medicine Clinic, LLC | P1/2 | CCC |
| Purapo | All Natural Medicine Clinic, LLC | P1/2 | CCC |
| Purwet | All Natural Medicine Clinic, LLC | P1/2 | CCC |
Other indications for Purinf
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Reactive Arthritis | — | P1/2 | CCC · 48 |
| Guillain-Barre Syndrome | — | P1/2 | CCC · 48 |
| Post-Infectious Neuralgia | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Purinf in Post-Infectious Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/purinf-post-infectious-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →